宫颈癌同步放化疗中骨盆骨髓照射剂量与淋巴细胞毒性的关系
本研究纳入117例接受同步放化疗的宫颈癌患者,分析骨盆骨髓中低剂量照射参数与淋巴细胞毒性的相关性。结果显示淋巴细胞毒性发生率94.88%,3-4级发生率68.38%;多因素分析示V5、V10、V20、V30与淋巴细胞毒性显著相关,小体积亚组1-4级及3-4级淋巴细胞毒性相对风险均显著低于大体积亚组(P<0.05)。
要点
- 宫颈癌同步放化疗中淋巴细胞毒性发生率94.88%,3-4级为68.38%。
- 骨盆骨髓V5、V10、V20、V30与淋巴细胞毒性显著相关。
- 小体积亚组1-4级及3-4级淋巴细胞毒性相对风险均显著低于大体积亚组(P<0.05)。
核心结论
- 骨盆骨髓中低剂量照射与淋巴细胞毒性发生率存在显著相关性。
- 减少中低剂量照射体积可有效降低淋巴细胞毒性发生率。
研究设计与样本
- 研究纳入117例接受同步放化疗的宫颈癌患者,放疗包括外照射和近距离治疗。
- 剂量学参数包括骨盆骨髓V5、V10、V20、V30、V40、V50及平均剂量(D mean)。
- 淋巴细胞毒性依据两周期同步化疗后最低淋巴细胞计数计算。
- 按截断值将患者分为小体积亚组和大体积亚组。
主要发现
- 同步放化疗期间淋巴细胞毒性发生率为94.88%,3-4级毒性发生率为68.38%。
- 多因素分析显示V5、V10、V20、V30与淋巴细胞毒性显著相关。
- 小体积亚组1-4级和3-4级淋巴细胞毒性相对风险均显著低于大体积亚组(P<0.05)。
- Kaplan-Meier分析显示小体积亚组1-4级和3-4级淋巴细胞毒性发生率均显著低于大体积亚组(P<0.05)。
关键数值与推荐
- 剂量学参数包括V5、V10、V20、V30、V40、V50及D mean。
- 多因素分析示V5、V10、V20、V30与淋巴细胞毒性显著相关。
- 小体积亚组较大体积亚组1-4级和3-4级淋巴细胞毒性相对风险显著降低(P<0.05)。
临床怎么用
- 原文结论指出减少中低剂量照射体积可有效降低淋巴细胞毒性发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study is to verify the correlation between medium and low radiation doses of the pelvic-bone marrow and the incidence of lymphocytic toxicity during concurrent chemoradiotherapy for cervical cancer. MATERIALS AND METHODS: This research included 117 cervical cancer patients, who received concurrent chemoradiotherapy. Radiotherapy included external-beam radiation therapy and brachytherapy. The dosimetry parameters include the Volume receiving 5 Gy (V5), 10 Gy (V10), 20 Gy (V20), 30 Gy (V30), 40 Gy (V40), 50 Gy (V50), and the mean dose (D mean) of the bone marrow. Lymphocytic toxicity was calculated from lowest lymphocytic count after two cycles of concurrent chemotherapy. RESULTS: During concurrent chemoradiotherapy, the incidence of lymphocytic toxicity is 94.88%. The incidence of grade 3-4 toxicity is 68.38%. Multivariate analysis findings show that the dosimetry parameters V5, V10, V20, and V30 are significantly correlated with lymphocytic toxicity. The patients are divided into small-volume subgroups and large-volume subgroups based on the cutoff values. The relative risk of both grade 1-4 and grade 3-4 lymphocytic toxicity is significantly lower in the small-volume subgroups than in the large-volume subgroups (P < 0.05). Kaplan-Meier analysis shows that the incidence of both grade 1-4 and grade 3-4 lymphocytic toxicity of the small-volume subgroups is significantly lower than that of the large-volume subgroups (P < 0.05). CONCLUSION: There is a significant correlation between a medium and low dose of pelvic-bone-marrow radiation and incidence of lymphocytic toxicity. Reducing the volume of medium and low radiation doses could effectively reduce incidence of lymphocytic toxicity.
引用
- Zhang BZ, Li Y, Xu LM, et al. The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer. Radiat Oncol. 2023. PMID: 36658595. doi:10.1186/s13014-023-02205-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。